Lupin hits a new high

Lupin over the weekend announced the launch of Darunavir Tablets, 600 mg and 800 mg, which is a generic equivalent of Prezista Tablets of Janssen Products.

Darunavir Tablets, 600 mg and 800 mg (RLD Prezista) had estimated annual sales of USD 308 million in the U.S. (IQVIA MAT March 2023).

The drug is taken with other HIV drugs to help control HIV infection. It aids in decreasing the amount of HIV in one's body so that the immune system can work better.

And four days ago, the company’s wholly-owned subsidiary, Novel Laboratories Inc, received approval from the US FDA for its abbreviated new drug application for diazepam rectal gel.

The company also announced a strategic pact with Enzene Biosciences to launch cetuximab in India, the first biosimilar developed for the intravenous infusion. Cetuximab has received approval from the Drug Controller General of India (DCGI) for its effectiveness in treating head and neck cancer.

Thus with so much news coming from the company over the past few couple of days, the mood on the counter is positive. The stock today opened almost 1% higher at Rs.823.15 and rose over 1.5% to hit a new 52-week high at Rs.830.30. Its currently trading at Rs.822 levels.